Benefits of ambulatory oxygen during physical activity in patients with COPD who desaturate only during exercise
Long-term oxygen is standard of care therapy for COPD patients hypoxemic at rest. Evidence of benefit is less clear for COPD patients hypoxemic only during ambulation. We studied effects of ambulatory O<sub>2</sub>, to be used during physical activity, in COPD patients normoxic at rest but hypoxemic (SpO<sub>2</sub><88%) during a 6-min walk test (6MWT). Subjects with COPD, 70±9 years, 42% female, FEV<sub>1</sub>% predicted 40±19, resting PaO<sub>2</sub> 9.1±0.9 kPa, who were willing to be physically active were included. They were randomized to supplemental O<sub>2</sub> (liquid oxygen in a 1.5 kg device, Helios Plus 300) during physical activity (n=78, O<sub>2</sub> group) or no supplemental O<sub>2</sub> (n=77, control group) for 6 months. All received regular motivational telephone interviews by a physiotherapist, encouraging ≥150 min of physical activity/week; daily physical activity time was recorded in a diary. O<sub>2</sub> group subjects recorded daily O<sub>2</sub> use time. Adherence to supplemental O<sub>2</sub> was defined as ≥70% of physical activity time. At baseline and 6 months, subjects performed spirometry and 6MWT (breathing air); symptoms were assessed by COPD Assessment Test (CAT). There were no significant differences between groups at baseline and change at 6 months did not differ between groups (Table). In conclusion, we obtained no evidence of supplemental O<sub>2</sub> benefit for COPD subjects who desaturate only during ambulation. <table-wrap><object-id>erj;64/suppl_68/PA1365/TB1</object-id><object-id>T1</object-id><object-id>TB1</object-id><table><colgroup><col></col><col></col><col></col><col></col><col></col><col></col></colgroup><tbody><tr><td></td><td> O<sub>2</sub> group </td><td> O<sub>2</sub> group </td><td> Control group </td><td> Control group </td><td> P-value: change between groups </td></tr><tr><td></td><td> Baseline n=64 </td><td> 6 months n=64 </td><td> Baseline n=64 </td><td> 6 months n=64 </td><td> </td></tr><tr><td>6 MWD (m)</td><td>353</td><td>334</td><td>383</td><td>375</td><td>0.09</td></tr><tr><td>FEV<sub>1</sub> (L)</td><td>0.97</td><td>0.92</td><td>1.08</td><td>1.03</td><td>0.61</td></tr><tr><td>CAT</td><td>17</td><td>17</td><td>17</td><td>17</td><td>0.83</td></tr></tbody></table></table-wrap>
Authors
- Milla Katajisto
- Maria Nykvist
- Annelie Behndig (ORCID: https://orcid.org/0000-0002-1533-9002)
- Kjell Larsson (ORCID: https://orcid.org/0000-0003-2737-4208)
- Christer Janson (ORCID: https://orcid.org/0000-0001-5093-6980)
- Richard Casaburi (ORCID: https://orcid.org/0000-0002-8851-8589)
- Karin Wadell (ORCID: https://orcid.org/0000-0001-7334-8698)
- Andreas Palm (ORCID: https://orcid.org/0000-0002-0590-0417)
- Ingegerd Margareta Emtner
Institutions
- Uppsala University (SE)
- University of Helsinki (FI)
- Uppsala University Hospital (SE)
- UCLA Medical Center (US)
- Karolinska Institutet (SE)
- Physiotherapy New Zealand (NZ)
- Svenska Örtmedicinska Institute (SE)
- Harbor–UCLA Medical Center (US)
- Umeå University (SE)
Publication Details
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1183/13993003.congress-2024.pa1365
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00